Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells

被引:39
作者
Carter, B. Z.
Mak, D. H.
Woessner, R. [2 ]
Gross, S. [2 ]
Schober, W. D.
Estrov, Z. [3 ]
Kantarjian, H. [3 ]
Andreeff, M. [1 ,3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Stem Cell Transplantat & Cellular Therapy, Unit 448, Houston, TX 77030 USA
[2] Array BioPharma Inc, Boulder, CO USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
KSP inhibitor ARRY-520; Eg5; cell cycle; apoptosis; mitochondrial pathway; AML; DRUG-INDUCED APOPTOSIS; INDEPENDENT PATHWAYS; CANCER CELLS; DNA-DAMAGE; IN-VIVO; PROTEIN; LEUKEMIA; P53; ACTIVATION; PACLITAXEL;
D O I
10.1038/leu.2009.101
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Kinesin spindle protein (KSP), a microtubule-associated motor protein essential for cell cycle progression, is overexpressed in many cancers and is a potential anti-tumor target. We found that inhibition of KSP by a selective inhibitor, ARRY-520, blocked cell cycle progression, leading to apoptosis in acute myeloid leukemia cell lines that express high levels of KSP. Knockdown of p53, overexpression of XIAP and mutation in caspase-8 did not significantly affect sensitivity to ARRY-520, suggesting that the response is independent of p53, XIAP and the extrinsic apoptotic pathway. Although ARRY-520 induced mitotic arrest in both HL-60 and Bcl-2-overexpressing HL-60Bcl-2 cells, cell death was blunted in HL-60Bcl-2 cells, suggesting that the apoptotic program is executed through the mitochondrial pathway. Accordingly, inhibition of Bcl-2 by ABT-737 was synergistic with ARRY-520 in HL-60Bcl-2 cells. Furthermore, ARRY-520 increased Bim protein levels prior to caspase activation in HL-60 cells. ARRY-520 significantly inhibited tumor growth of xenografts in SCID mice and inhibited AML blast but not normal colony formation, supporting a critical role for KSP in proliferation of leukemic progenitor cells. These results demonstrate that ARRY-520 potently induces cell cycle block and subsequent death in leukemic cells via the mitochondrial pathway and has the potential to eradicate AML progenitor cells. Leukemia (2009) 23, 1755-1762; doi: 10.1038/leu.2009.101; published online 21 May 2009
引用
收藏
页码:1755 / 1762
页数:8
相关论文
共 36 条
[1]  
[Anonymous], P AM ASS CANC RES AN
[2]   Phosphorylation by p34(cdc2) regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo [J].
Blangy, A ;
Lane, HA ;
dHerin, P ;
Harper, M ;
Kress, M ;
Nigg, EA .
CELL, 1995, 83 (07) :1159-1169
[3]  
Burris H. III, 2003, EJC Supplements, V1, pS172, DOI 10.1016/S1359-6349(03)90602-1
[4]   Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5 [J].
Carter, Bing Z. ;
Mak, Duncan H. ;
Schober, Wendy D. ;
Dietrich, Martin F. ;
Pinilla, Clernencia ;
VassileV, Lyubornir T. ;
Reed, John C. ;
Andreeff, Michael .
BLOOD, 2008, 111 (07) :3742-3750
[5]   Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML - Overcoming Imatinib resistance [J].
Carter, Bing Z. ;
Mak, Duncan H. ;
Shi, Yuexi ;
Schober, Wendy D. ;
Wang, Rui-Yu ;
Konopleva, Marina ;
Koller, Erich ;
Dean, Nicholas M. ;
Andreeff, Michael .
CELL CYCLE, 2006, 5 (19) :2223-2229
[6]   Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia [J].
Carter, BZ ;
Milella, M ;
Tsao, T ;
McQueen, T ;
Schober, WD ;
Hu, W ;
Dean, NM ;
Steelman, L ;
McCubrey, JA ;
Andreeff, M .
LEUKEMIA, 2003, 17 (11) :2081-2089
[7]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[8]  
CHU Q, 2003, P AN M AM SOC CLIN, V22, P131
[9]   XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage [J].
Datta, R ;
Oki, E ;
Endo, K ;
Biedermann, V ;
Ren, J ;
Kufe, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (41) :31733-31738
[10]  
Estève MA, 2007, CURR CANCER DRUG TAR, V7, P713